Prometic Announces Realignment of its Clinical Program Priorities for 2018
LAVAL, QC, Feb. 20, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") today provided an update regarding its clinical development programs and confirmation of its priorities regarding its lead drug candidates.
PBI-4050 and follow-on analogs, PBI-4547 & PBI-4425
"Idiopathic pulmonary fibrosis (IPF) is now priority No.1 for PBI-4050" stated Pierre Laurin, President and CEO of Prometic. "IPF remains to this day a significant unmet medical need affecting hundreds of thousands of patients with an established market value measured in $billions. The clinical efficacy demonstrated so far in multiple phase 2 clinical trials combined with an impressive safety and tolerability profile gives us great confidence in PBI-4050's ability to efficiently address fibrotic diseases."
Read more: https://www.newswire.ca/news-releases/prometic-announces-realignment-of-its-clinical-program-priorities-for-2018-674637943.html
PBI-4050 and follow-on analogs, PBI-4547 & PBI-4425
"Idiopathic pulmonary fibrosis (IPF) is now priority No.1 for PBI-4050" stated Pierre Laurin, President and CEO of Prometic. "IPF remains to this day a significant unmet medical need affecting hundreds of thousands of patients with an established market value measured in $billions. The clinical efficacy demonstrated so far in multiple phase 2 clinical trials combined with an impressive safety and tolerability profile gives us great confidence in PBI-4050's ability to efficiently address fibrotic diseases."
Read more: https://www.newswire.ca/news-releases/prometic-announces-realignment-of-its-clinical-program-priorities-for-2018-674637943.html